Patent application number | Description | Published |
20080264416 | Method of Treating Diabetes Mellitus in a Patient - Dosages of inhaled insulin are controlled within a narrow range by controlling the total volume of air inhaled by a patient. By repeatedly delivering aerosolized insulin with the same total inhaled volume of air, the amount of insulin delivered to the patient each time is consistent. A device for delivering insulin by inhalation is disclosed which device comprises a means for measuring inhaled volume and for halting inhalation at a pre-determined point. The device also comprises an adjustable means for applying various amounts of force to a container of formulation to expel different amounts of drug from the container based on the force applied. | 10-30-2008 |
20100209538 | PH-MODULATED FORMULATIONS FOR PULMONARY DELIVERY - An aerosolizable formulation comprised of a drug, a carrier and pH affecting component is disclosed. The drug is dissolved in the formulation at a concentration above which it remains in solution at neutral pH. This increases the concentration of the drug in solution making it possible to administer larger amounts of drug with the same or a smaller volume of formulation. When the formulation is aerosolized to small particles and inhaled into human lungs in small volumes (e.g. 0.05 to 0.5 mL) the fluids in the lungs neutralize the formulation causing the drug to participate out of solution. This results in the drug being delivered at a controlled rate below the rate at which drug is administered from a formulation initially at a neutral pH. | 08-19-2010 |
20110182831 | SYSTEMS AND METHODS USED IN CONJUNCTION WITH NICOTINE VACCINES FOR EFFECTING CESSATION OF TOBACCO USE - The invention relates generally to a system and method for treating conditions responsive to nicotine therapy. More specifically, the invention relates to administering a nicotine vaccine or nicotine antibody along with pulmonary administration of a nicotine containing formulation to affect smoking cessation. | 07-28-2011 |
20110312017 | DIAGNOSIS OF ENTRY OF GASTROINTESTINAL CONTENTS INTO RESPIRATORY TRACT OF HUMANS AND ANIMALS - A method of diagnosing respiratory fluid in a patient suffering from gastro esophageal reflux disease (GERD) is disclosed. The method comprises (1) orally administering to a subject suspected of suffering from gastro esophageal reflux disease (GERD), a formulation comprised of a plurality of particles comprised of a biocompatible polymer (e.g. carnauba wax) and a detectable, non-radioactive label (e.g. a fluorescent label), (2) allowing the formulation to remain in the subject over a period of time during which the subject would be expected to aspirate the formulation, (3) collecting respiratory fluid from the subject, and (4) analyzing the respiratory fluid to determine if the fluid contains the detectable label, and thereby determining if the subject regurgitates fluid into the respiratory tract. Alternatively, or additionally, a subject swallows a label that is not destroyed in the respiratory tract, or in the gastrointestinal tract, which further has the property that it is absorbed from the respiratory tract but not from the gastrointestinal tract. The presence of the label is then analyzed in blood, or, if the substance is excreted from blood to urine, in urine samples. The qualitative analysis can be also expanded into quantitative analysis, enabling the estimation of either the concentration, or the amount, or both, of the gastrointestinal contents that entered the respiratory tract. | 12-22-2011 |
20120177693 | DEEP LUNG PULMONARY DELIVERY OF TREPROSTINIL - Administration of aerosolized Treprostinil formulations may provide a more homogeneous lung deposition of treprostinil, whereby making deep lung delivery possible. | 07-12-2012 |
20120305011 | Systems and Methods for Effecting Cessation of Tobacco Use - The invention relates generally to a system and method for treating conditions responsive to nicotine therapy. More specifically, the invention relates to pulmonary administration of a nicotine containing formulation to effect smoking cessation. | 12-06-2012 |
20140194502 | DIAGNOSIS AND TREATMENT METHODS FOR ENTRY OF GASTROINTESTINAL CONTENTS INTO RESPIRATORY TRACT - A method of diagnosing in a subject for the purpose of determining if the subject's gastrointestinal contents has entered the subject's respiratory tract. The qualitative analysis can be also expanded into quantitative analysis, enabling the estimation of either the concentration, or the amount, or both, of the gastrointestinal contents that entered the respiratory tract. The invention also provides methods of treatment based on the identification of aspiration using the methods of the invention. | 07-10-2014 |
20140194503 | DIAGNOSIS AND TREATMENT METHODS FOR ENTRY OF GASTROINTESTINAL CONTENTS INTO RESPIRATORY TRACT - A method of diagnosing in a subject for the purpose of determining if the subject's gastrointestinal contents has entered the subject's respiratory tract. The qualitative analysis can be also expanded into quantitative analysis, enabling the estimation of either the concentration, or the amount, or both, of the gastrointestinal contents that entered the respiratory tract. The invention also provides methods of treatment based on the identification of aspiration using the methods of the invention. | 07-10-2014 |
20140194504 | DIAGNOSIS AND TREATMENT METHODS FOR ENTRY OF GASTROINTESTINAL CONTENTS INTO RESPIRATORY TRACT - A method of diagnosing in a subject for the purpose of determining if the subject's gastrointestinal contents has entered the subject's respiratory tract. The qualitative analysis can be also expanded into quantitative analysis, enabling the estimation of either the concentration, or the amount, or both, of the gastrointestinal contents that entered the respiratory tract. The invention also provides methods of treatment based on the identification of aspiration using the methods of the invention. | 07-10-2014 |
20140261474 | METHODS FOR INHALATION OF SMOKE-FREE NICOTINE - The invention relates generally to a system or kit that delivers nicotine to target the regions of the respiratory tract to achieve the maximum impact on craving with a minimum number of unwanted sensations. More specifically, the invention relates to pulmonary administration of nicotine from nicotine inhalation systems that target delivery to the deep lung, minimizing deposition in the upper and central airways. | 09-18-2014 |
Patent application number | Description | Published |
20090004249 | DUAL RELEASE NICOTINE FORMULATIONS, AND SYSTEMS AND METHODS FOR THEIR USE - This invention relates generally to a method to provide habitual tobacco users with products, methods and apparatus to reduce and eventually terminate their dependence on nicotine containing products. More specifically, the invention relates to a nicotine-based medicament that is formulated in such a way as to effectively reduce or eliminate the sensations of craving associated with addictive nicotine use. | 01-01-2009 |
20090004250 | DUAL RELEASE NICOTINE FORMULATIONS, AND SYSTEMS AND METHODS FOR THEIR USE - This invention relates generally to a method to provide habitual tobacco users with products, methods and apparatus to reduce and eventually terminate their dependence on nicotine containing products. More specifically, the invention relates to a nicotine-based medicament that is formulated in such a way as to effectively reduce or eliminate the sensations of craving associated with addictive nicotine use. | 01-01-2009 |
20090005423 | SYSTEMS AND METHODS FOR EFFECTING CESSATION OF TOBACCO USE - The invention relates generally to a system and method for treating conditions responsive to nicotine therapy. More specifically, the invention relates to pulmonary administration of a nicotine containing formulation to effect smoking cessation. | 01-01-2009 |
20090241950 | METHOD OF TREATING DIABETES MELLITUS IN A PATIENT - The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient=s breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation. The device includes a sensor which is preferably electronic which measures inspiratory flow and volume which measurement can be used to control the point of drug release. | 10-01-2009 |